Climb Bio Reports CLYM116/MIL116 APRIL Suppression and Gd-IgA1 Reduction

The companies reported more than 90% free APRIL suppression sustained through 12 weeks and an approximately 70% reduction in Gd-IgA1 at 12 weeks. The reported half-life was approximately 33 days. NAVIGATE-2 Phase 2 is enrolling, with initial data expected in the first half of next year; a global Phase 3 trial is also expected to start next year.